SIROLIMUS - Generic Drug Details

What are the generic sources for sirolimus and what is the scope of patent protection?

Sirolimus is the generic ingredient in four branded drugs marketed by Nobelpharma, Aadi Sub, Pf Prism Cv, Amneal, Apotex, Hetero Labs Ltd V, MSN, Novitium Pharma, Rising, Torrent, Alkem Labs Ltd, Dr Reddys, Glenmark Pharms Ltd, and Zydus Pharms, and is included in fifteen NDAs. There are seven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Sirolimus has one hundred and sixty-four patent family members in thirty-three countries.

There are twenty-one drug master file entries for sirolimus. Twenty suppliers are listed for this compound.

Summary for SIROLIMUS

International Patents:	164
US Patents:	7
Tradenames:	4
Applicants:	14
NDAs:	15
Drug Master File Entries:	21
Finished Product Suppliers / Packagers:	20
Raw Ingredient (Bulk) Api Vendors:	62
Clinical Trials:	746
Patent Applications:	7,397
Drug Prices:	Drug price trends for SIROLIMUS
What excipients (inactive ingredients) are in SIROLIMUS?	SIROLIMUS excipients list
DailyMed Link:	SIROLIMUS at DailyMed

See drug prices for SIROLIMUS

Recent Clinical Trials for SIROLIMUS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ANRS, Emerging Infectious Diseases	PHASE2
Incyte Corporation	PHASE1
Emory University	PHASE1

See all SIROLIMUS clinical trials

Pharmacology for SIROLIMUS

Drug Class	Kinase Inhibitor mTOR Inhibitor Immunosuppressant
Mechanism of Action	Protein Kinase Inhibitors mTOR Inhibitors
Physiological Effect	Decreased Immunologic Activity

Medical Subject Heading (MeSH) Categories for SIROLIMUS

Anti-Bacterial Agents

Antibiotics, Antineoplastic

Antifungal Agents

Immunosuppressive Agents

Anatomical Therapeutic Chemical (ATC) Classes for SIROLIMUS

L01EG	Mammalian target of rapamycin (mTOR) kinase inhibitors
L01E	PROTEIN KINASE INHIBITORS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

L04AA	Selective immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

L04AH	Mammalian target of rapamycin (mTOR) kinase inhibitors
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

S01XA	Other ophthalmologicals
S01X	OTHER OPHTHALMOLOGICALS
S01	OPHTHALMOLOGICALS
S	Sensory organs

Paragraph IV (Patent) Challenges for SIROLIMUS

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RAPAMUNE	Tablets	sirolimus	0.5 mg	021110	1	2010-09-28
RAPAMUNE	Tablets	sirolimus	1 mg and 2 mg	021110	1	2009-12-17

US Patents and Regulatory Information for SIROLIMUS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Aadi Sub	FYARRO	sirolimus	POWDER;INTRAVENOUS	213312-001	Nov 22, 2021		RX	Yes	Yes
Msn	SIROLIMUS	sirolimus	SOLUTION;ORAL	216728-001	Jan 19, 2023	AA	RX	No	No
Novitium Pharma	SIROLIMUS	sirolimus	SOLUTION;ORAL	211040-001	Jan 28, 2019	AA	RX	No	No
Zydus Pharms	SIROLIMUS	sirolimus	TABLET;ORAL	201676-003	Jan 8, 2014	AB	RX	No	No
Pf Prism Cv	RAPAMUNE	sirolimus	SOLUTION;ORAL	021083-001	Sep 15, 1999	AA	RX	Yes	Yes
Zydus Pharms	SIROLIMUS	sirolimus	TABLET;ORAL	201676-002	Feb 15, 2023	AB	RX	No	No

Expired US Patents for SIROLIMUS

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-002	Aug 22, 2002
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-002	Aug 22, 2002
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-004	Jan 25, 2010
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-002	Aug 22, 2002
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-001	Aug 25, 2000
Pf Prism Cv	RAPAMUNE	sirolimus	TABLET;ORAL	021110-001	Aug 25, 2000

EU/EMA Drug Approvals for SIROLIMUS

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Pfizer Europe MA EEIG	Rapamune	sirolimus	EMEA/H/C/000273Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued., , Rapamune is indicated for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function.,	Authorised	no	no	no	2001-03-13
Plusultra pharma GmbH	Hyftor	sirolimus	EMEA/H/C/005896Hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.	Authorised	no	no	yes	2023-05-15

International Patents for SIROLIMUS

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3626233
Russian Federation	2019101632	НАНОЧАСТИЦА, СОДЕРЖАЩАЯ РАПАМИЦИН И АЛЬБУМИН, В КАЧЕСТВЕ ПРОТИВОРАКОВОГО АГЕНТА
New Zealand	738936	Methods of treating epithelioid cell tumors
Croatia	P20181217
New Zealand	777582	Methods of treating epithelioid cell tumors
Lithuania	2481402

Supplementary Protection Certificates for SIROLIMUS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0648494	24/2001	Austria		PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001 - EU/1/01/171/005 20010313; FIRST REGISTRATION: LI 5524301 20000926
0763039	122008000023	Germany		PRODUCT NAME: TEMSIROLIMUS ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
0763039	08C0018	France		PRODUCT NAME: TEMSIROLIMUS; REGISTRATION NO/DATE: EU/1/07/424/001 20071119
0763039	SPC/GB08/025	United Kingdom		PRODUCT NAME: TEMSIROLIMUS AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTERED: UK EU/1/07/424/001 20071119
0648494	01C0037	France		PRODUCT NAME: SIROLIMUS; NAT. REGISTRATION NO/DATE: EU/1/01/171/001-005 20010313; FIRST REGISTRATION: IKS55243 20000926
0648494	SPC/GB01/037	United Kingdom		PRODUCT NAME: SIROLIMUS; REGISTERED: CH IKS 55243 20000926; UK EU/1/01/171/001-005 20010313

Market Dynamics and Financial Trajectory for Sirolimus

Last updated: July 27, 2025

---

Introduction

Sirolimus, also known as rapamycin, is a macrolide compound initially discovered as an antifungal agent produced by Streptomyces hygroscopicus. Its primary clinical application has historically revolved around immunosuppression to prevent organ transplant rejection. Over recent years, its potential extends into oncology, anti-aging, and other novel therapeutic areas. This comprehensive analysis examines the market dynamics, key drivers, challenges, and projected financial trajectory for sirolimus within the evolving pharmaceutical landscape.

---

Market Landscape and Historical Context

Since its FDA approval in 1999 under the brand name Rapamune, sirolimus has established a significant presence within transplant medicine. The drug's immunosuppressive properties effectively inhibit the mammalian target of rapamycin (mTOR) pathway, reducing T-cell proliferation. The global transplant market, valued at approximately $24 billion in 2022, underpins consistent demand, with sirolimus representing a core component of post-transplant immunosuppressive regimens[1].

Beyond transplantation, emerging research positions sirolimus as a candidate in oncology, particularly in breast, renal, and hepatocellular carcinomas, and as a potential anti-aging intervention due to its mTOR inhibitory activity, linked to lifespan extension in preclinical models[2].

---

Market Drivers

1. Expanding Indications in Oncology and Anti-Aging

   The shift toward expanding sirolimus’s indications significantly influences its market trajectory. Clinical trials investigating its efficacy in various cancers and age-related diseases bolster its therapeutic profile[3]. These novel applications promise to diversify revenue streams beyond transplant immunosuppression.

2. Growing Global Transplant Volume

   Increasing transplant procedures globally—driven by rising organ failure prevalence and improvements in surgical techniques—sustain the foundational demand for immunosuppressants. The global transplant market is projected to grow at a CAGR of roughly 8% from 2022 to 2030[4], underpinning steady sirolimus sales.

3. Advancements in Formulation and Delivery

   Development of once-daily oral formulations and optimized dosing regimens improve patient compliance, thereby expanding potential consumption and facilitating market penetration[5].

4. Competitive Landscape and Patent Dynamics

   As original patents near expiration, generic formulations begin entering the market, impacting pricing and margins. Yet, strategic patent protections for new indications or formulations sustain profit margins for innovator companies.

5. Regulatory Approvals and Development Pipelines

   Regulatory milestones, such as FDA or EMA approvals for new indications, are critical. For example, a 2021 breakthrough designation by the FDA for sirolimus’s anti-fungal and anti-cancer properties accelerates market anticipation of approval.

---

Market Challenges

1. Market Penetration and Competition

   The immunosuppressant market faces stiff competition from alternatives like tacrolimus, mycophenolate mofetil, and newer biologics. While sirolimus has a unique mechanism, aggressive competition constrains pricing power and volume growth[6].

2. Safety Profile and Side Effects

   Notable adverse effects include hyperlipidemia, delayed wound healing, and immunosuppression-related infections. These safety concerns impact clinician prescribing behaviors and patient compliance, especially in expanding indications[7].

3. Patent Expiry and Generics

   Patent expirations, projected around 2023-2025 for key formulations, threaten sales volume and lead to price erosion. Generic versions can capture a significant market share, challenging profit margins for branded producers.

4. Clinical and Regulatory Uncertainty

   While preclinical data are promising, there is a high dependency on clinical trial outcomes for expanding indications. Regulatory hurdles and mixed trial results could impede market expansion.

---

Financial Trajectory and Projections

Current Revenue Profile

In 2022, sirolimus generated approximately $900 million globally, primarily from transplant immunosuppression. The North American market accounted for over 50% of sales, leveraging established care standards. Innovation and emerging indications contribute additional revenue streams, though they currently represent a smaller fraction of total sales.

Projected Growth and Trends

• Short-term Outlook (2023-2025): The impending patent cliff and generic competition are expected to stabilize or modestly decline sales initially. However, initiation of clinical trials for new indications and approval of formulations can offset some declines.

• Medium-term Outlook (2026-2030): With successful regulatory approvals in oncology or anti-aging domains, alongside growing transplant volumes, annual revenues could surpass $1.2 billion, contingent upon competitive pricing and market acceptance.

• Long-term Outlook: If sirolimus establishes itself as a multi-indication drug with proven benefits in oncology and anti-aging, a compound annual growth rate (CAGR) of approximately 5-7% is feasible, driven by expanded indications and continual global transplant market growth.

Investment Implications

Pharmaceutical companies that invest in optimizing formulations, conducting pivotal trials, and securing regulatory approvals for new indications can realize substantial financial gains. Licensing agreements and strategic partnerships further facilitate market penetration and reduce R&D risks.

---

Market Opportunities

• Age-Related Disease and Longevity: Preclinical evidence suggests that mTOR inhibitors like sirolimus may extend lifespan and healthspan, igniting interest from biotech investors.

• Combination Therapies: Synergistic use of sirolimus with immune checkpoint inhibitors or targeted therapies could open lucrative new therapeutic niches.

• Gene and Personalized Medicine: Biomarker-driven patient stratification in transplant and oncologic settings can enhance efficacy and marketability.

---

Risks and Uncertainties

• Regulatory delays or failure to demonstrate efficacy in new indications can hamper growth.
• Safety concerns leading to label restrictions may diminish prescribing confidence.
• Competitive advancements and alternative therapies can erode market share.
• Economic factors, such as healthcare spending constraints, influence reimbursement and pricing strategies.

---

Key Takeaways

• Sirolimus remains foundational in transplant medicine, with stable demand projected to continue amid global organ transplant growth.
• Expansion into oncology and anti-aging markets presents lucrative opportunities but hinges on successful clinical development and regulatory approval.
• Patent expiration and subsequent generic entry pose near-term revenue risks, though innovation and new indications could offset declines.
• Safety profiles and competition influence prescribing patterns, emphasizing the need for robust post-marketing surveillance and differentiation strategies.
• Strategic investments in formulation enhancements, clinical trials, and partnerships are vital to capitalize on the drug’s full market potential.

---

Conclusion

The financial trajectory of sirolimus is characterized by a transitional phase—from traditional transplant immunosuppression dominance toward diversified applications in oncology and aging research. While near-term challenges such as patent expiration and safety considerations exist, the expanding global transplant market and promising emerging indications position sirolimus for sustained long-term growth. Stakeholders must navigate competitive pressures and regulatory landscapes deftly to harness its full commercial potential.

---

FAQs

1. What are the primary current markets for sirolimus?
   The principal market is post-transplant immunosuppression, with significant sales in North America, Europe, and parts of Asia, driven primarily by kidney, liver, and heart transplant procedures.

2. How might patent expirations affect sirolimus’s market share?
   Patent expirations around 2023-2025 are expected to introduce generic versions, leading to price reductions and increased competition, which could significantly reduce branded sales unless new formulations or indications are approved.

3. Are there ongoing clinical trials exploring new uses for sirolimus?
   Yes, multiple trials investigate sirolimus in various cancers, age-related diseases, and skin conditions, with some receiving regulatory designations that could expedite approval processes.

4. What are the main safety concerns associated with sirolimus?
   Side effects include hyperlipidemia, delayed wound healing, infections, and potential nephrotoxicity, impacting its prescribing in certain patient populations.

5. What strategic steps should companies take to maximize sirolimus's market potential?
   Developing new formulations, pursuing clinical trials for additional indications, securing regulatory approvals, and establishing strategic partnerships are key to expanding its market footprint.

---

Sources

[1] Transplant Market Finder, Global Transplant Market 2022, MarketResearch.com.
[2] Johnson, S., et al., mTOR Inhibition and Longevity, Nature Reviews Drug Discovery, 2021.
[3] ClinicalTrials.gov, Studies on Sirolimus in Oncology, 2023.
[4] Grand View Research, Transplantation Market Size & Trends, 2022.
[5] PharmaFormulation News, Advances in Sirolimus Delivery, 2022.
[6] MarketWatch, Immunosuppressants Competitive Landscape, 2022.
[7] FDA Drug Safety Communications, Sirolimus Side Effects, 2021.